These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28393576)

  • 41. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
    Nagler M; Angelillo-Scherrer A; Méan M; Limacher A; Abbal C; Righini M; Beer JH; Osterwalder J; Frauchiger B; Aschwanden M; Matter CM; Kucher N; Cornuz J; Banyai M; Husmann M; Staub D; Mazzolai L; Hugli O; Rodondi N; Aujesky D
    J Thromb Haemost; 2017 Nov; 15(11):2165-2175. PubMed ID: 28834238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study.
    Eischer L; Kammer M; Traby L; Kyrle PA; Eichinger S
    J Thromb Haemost; 2017 Jul; 15(7):1368-1374. PubMed ID: 28407356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study.
    Lai N; Jones AE; Johnson SA; Witt DM
    J Thromb Thrombolysis; 2021 Aug; 52(2):414-418. PubMed ID: 33486650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study).
    Bradbury C; Fletcher K; Sun Y; Heneghan C; Gardiner C; Roalfe A; Hardy P; McCahon D; Heritage G; Shackleford H; Hobbs FR; Fitzmaurice D
    Br J Haematol; 2020 Mar; 188(6):962-975. PubMed ID: 31713863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study.
    Figueroa R; Alfonso A; López-Picazo J; Gil-Bazo I; García-Mouriz A; Hermida J; Páramo JA; Lecumberri R
    PLoS One; 2018; 13(8):e0200220. PubMed ID: 30071038
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors.
    Lecumberri R; Ruiz-Artacho P; Tzoran I; Brenner B; Farge-Bancel D; Ay C; Rosa V; Francisco I; Hernández-Blasco LM; Trujillo-Santos J; Monreal M;
    Thromb Haemost; 2022 Sep; 122(9):1594-1602. PubMed ID: 35189661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Venous Thromboembolism in Patients With Thrombocytopenia: Risk Factors, Treatment, and Outcome.
    Baelum JK; Moe EE; Nybo M; Vinholt PJ
    Clin Appl Thromb Hemost; 2017 May; 23(4):345-350. PubMed ID: 26512063
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study.
    Le Guenno G; Guieze R; Audia S; Khellaf M; Michel M; Bonnotte B; Ruivard M; Godeau B
    Intern Med J; 2019 Sep; 49(9):1154-1162. PubMed ID: 30816621
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention.
    Gerber DE; Segal JB; Levy MY; Kane J; Jones RJ; Streiff MB
    Blood; 2008 Aug; 112(3):504-10. PubMed ID: 18480425
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism.
    Yamashita Y; Amano H; Morimoto T; Kadota K; Hata R; Matsushita K; Osakada K; Sano A; Takase T; Hiramori S; Kim K; Oi M; Akao M; Kobayashi Y; Toyofuku M; Inoko M; Tada T; Chen PM; Murata K; Tsuyuki Y; Nishimoto Y; Sasa T; Sakamoto J; Kinoshita M; Togi K; Mabuchi H; Takabayashi K; Kato T; Ono K; Kimura T;
    J Thromb Thrombolysis; 2022 Jan; 53(1):182-190. PubMed ID: 34228248
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Periprocedural anticoagulation management of patients with venous thromboembolism.
    McBane RD; Wysokinski WE; Daniels PR; Litin SC; Slusser J; Hodge DO; Dowling NF; Heit JA
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):442-8. PubMed ID: 20139361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer.
    Patell R; Hsu C; Shi M; Grosso MA; Duggal A; Buller HR; Raskob G; Zwicker JI
    Haematologica; 2024 Jun; 109(6):1849-1856. PubMed ID: 37855029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
    Park H; Jones BL; Huang PL; Kang HR; Dietrich EA; DeRemer CE; Lo-Ciganic WH
    Ann Pharmacother; 2023 Dec; 57(12):1349-1360. PubMed ID: 36999519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.
    Labrador J; González-Rivero J; Monroy R; Lozano FS; López-Corral L; Caballero MD; Bastida JM; González-Porras JR
    Thromb Res; 2016 Jun; 142():52-6. PubMed ID: 26922092
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.
    Barco S; Granziera S; Coppens M; Douxfils J; Nijkeuter M; Riva N; Vanassche T; Zhang G; Lin M; Kamphuisen PW; Cohen AT; Beyer-Westendorf J
    Thromb Haemost; 2019 Apr; 119(4):675-684. PubMed ID: 30731492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.
    Carrier M; Le Gal G; Wells PS; Rodger MA
    Ann Intern Med; 2010 May; 152(9):578-89. PubMed ID: 20439576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.